ELAN vs. ALNY, TEVA, GMAB, RPRX, BGNE, BMRN, VTRS, UTHR, SRPT, and RDY
Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical preparations" industry.
Elanco Animal Health (NYSE:ELAN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.
Alnylam Pharmaceuticals has lower revenue, but higher earnings than Elanco Animal Health. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Alnylam Pharmaceuticals has a net margin of -16.58% compared to Elanco Animal Health's net margin of -29.83%. Elanco Animal Health's return on equity of 5.98% beat Alnylam Pharmaceuticals' return on equity.
Elanco Animal Health has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 0.6% of Elanco Animal Health shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Elanco Animal Health presently has a consensus price target of $18.29, suggesting a potential upside of 6.62%. Alnylam Pharmaceuticals has a consensus price target of $216.19, suggesting a potential upside of 44.07%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Elanco Animal Health.
Alnylam Pharmaceuticals received 959 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 54.13% of users gave Elanco Animal Health an outperform vote.
In the previous week, Elanco Animal Health had 12 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 17 mentions for Elanco Animal Health and 5 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.11 beat Elanco Animal Health's score of 0.89 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.
Summary
Alnylam Pharmaceuticals beats Elanco Animal Health on 10 of the 18 factors compared between the two stocks.
Get Elanco Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elanco Animal Health Competitors List
Related Companies and Tools
